Premium
TESTIN was commonly hypermethylated and involved in the epithelial‐mesenchymal transition of endometrial cancer
Author(s) -
Dong Ruofan,
Pu Hong,
Wang Yuan,
Yu Jinjin,
Lian Kuixian,
Mao Caiping
Publication year - 2015
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12361
Subject(s) - endometrial cancer , medicine , cancer research , cancer
We previously reported frequent loss of TESTIN in human endometrial carcinoma, which significantly suppressed tumor proliferation and invasion. Herein, we further explored the mechanisms underlying TESTIN loss and its roles in the epithelial‐mesenchymal transition ( EMT , a key step for tumor spreading). Methylation‐specific PCR was performed to investigate the promoter status of TESTIN in a panel of endometrial cancer and normal endometrium tissues. The expression of TESTIN mRNA was determined by real‐time PCR . Up‐ and down‐regulation of TESTIN were achieved by transient transfection with pc DNA 3.1‐ TESTIN and sh RNA ‐ TESTIN plasmids, respectively. The EMT alterations were observed under the optical microscope and EMT ‐related markers were detected by real‐time PCR and western blot. Compared to the control (3.6%), TESTIN was hypermethylated in 43.7% endometrial cancer tissues (p < 0.001). Moreover, TESTIN hypermethylation was significantly correlated with advanced tumor stage, deep myometrial invasion and lymphatic node metastasis. In vitro , the demethylating agent dramatically restored the expression of TESTIN . In addition, up‐regulation of TESTIN significantly suppressed the EMT procedure; whereas down‐regulation of TESTIN enhanced EMT . In conclusion, we demonstrated that loss of TESTIN was mainly caused by hypermethylation, which might be a potent prognostic marker. Furthermore, we proved that TESTIN significantly suppressed the EMT procedure, proposing restoration of TESTIN to be a novel therapeutic strategy for endometrial carcinoma.